CRISPR Therapeutics Stock News

The Buzzing Gene-Editing Market Of Crispr Therapeutics

CRISPR Therapeutics: Roadblock Ahead

Overvalued stocks are easy to find using metrics which indicate a stock should trade for less. But these ones keep bucking their critics.

We are glad to announce that we have added Catherine Wood (Trades, Portfolio)'s ARK Investment Management as one of our Premium Gurus.

CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.

Want to play it safe in a volatile market? Go for these three top-notch healthcare picks.

Bear of the Day: CRISPR Therapeutics (CRSP)

The Clough funds all have impressive records. GLV previously paid a higher distribution yield even though it didn't earn as much as its two siblings, GLO and GLQ. That's been rectified with the big di

CRISPR Therapeutics AG (CRSP) closed at $168.81 in the latest trading session, marking a +0.61% move from the prior day.

On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ser

Which of these two hot gene therapy stocks is the better buy?

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR Therapeutics stock, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has plunged by 14% over the last 10 trading days, and it is down 10% over

One aspect of the ANEW ETF is focused on the bleeding edge of medical advances. Here's what you need to know if you're considering investing.